

"Express Mail" mailing label number	EL832895214US
Date of Deposit	4-09-04
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Printed Name	Signature
QUEEN Thomas	Queen Thomas

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	:	David Bleakman, et al.)
)
For	:	SELECTIVE IGLUR5 RECEPTOR)
		ANTAGONISTS FOR THE)
		TREATMENT OF MIGRAINE)
)
Docket No.	:	X-12149B)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) for consideration by the Examiner.

As permitted by 37 C.F.R. §1.98(d), Applicants refer to the parent application, Serial No. 10/009,655, filed December 11, 2001 for copies of the listed documents.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

Applicants request consideration of this information.

Respectfully submitted,

Alexander Wilson

Alexander Wilson
Attorney for Applicants
Registration No. 45,782
Phone: 317-277-0190

Eli Lilly and Company
Patent Division/AW
P.O. Box 6288
Indianapolis, Indiana 46206-6288

08 April 2004.

FORM PTO 1449 (modified)				Atty. Docket No. X-12149B		Serial No	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION				Applicants David Bleakman, et al.			
				Filing Date		Group	
U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Sub- class	Filing Date If Appropriate
	AA	5,670,516	9/23/97	Arnold, et al.			
	AB	5,356,902	10/18/94	Ornstein			
	AC	5,767,117	6/16/98	Moskowltz			
	AD	5,446,051	8/29/95	Ornstein			
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Sub- class	Translation
							yes no
	BA	WO 01/02367	1/11/01	PCT			
	BB	WO 98/45270	10/15/98	PCT			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	CA	Procter, et al., "Possible role of GluR5 glutamate receptors in spinal nociceptive processing in the anaesthetized rat," <i>Journal of Physiology</i> , 504, pgs. 101P-102P (1997)					
	CB	Nikam, et al., "The search for AMPA/Gly(N) receptor antagonists," <i>Drugs of the Future</i> , 24(10), pgs. 1107-1124 (1999)					
	CC	O'Neill, MJ, et al., "Decahydroisoquinolines: Novel competitive AMPA/kainite antagonists with neuroprotective effects in global cerebral ischaemia," <i>Neuropharmacology</i> , 37, pgs. 1211-1222 (1998)					
	CD	Proctor, MJ, et al., "Actions of kainite and AMPA selective glutamate receptor ligands on nociceptive processing in the spinal cord," <i>Neuropharmacology</i> , 37, pgs. 1287-1297 (1998)					
	CE	Bleakman, D., "Kainate receptor pharmacology and physiology," <i>Cellular and Molecular Life Sciences</i> , 56/7-8, pgs. 558-556 (1999)					
	CF	Simmons, RM, et al., "Kainate GluR5 receptor subtype mediates the nociceptive response to formalin in the rat," <i>Neuropharmacology</i> , 37(1), pgs. 25-36 (1998)					
	CG	National Library of Medicine (NLM), Bethesda, MD, US: Mitsilostas, DD, et al., "Non-NMDA glutamate receptors modulate capsaicin induced c-fos expression within trigeminal nucleus caudalis," <i>Database accession no. 100003939 & British Journal of Pharmacology</i> , 127(3), pgs. 623-630 (1999)					
	CH	Sahara, Y, et al., "Glutamate receptor subunits GluR5 and KA-2 are coexpressed in rat trigeminal ganglion neurons," <i>The Journal of Neuroscience</i> , 17(17), pgs. 6611-6620 (1997)					
	CI	Alam, Z., et al., "Plasma levels of neuroexcitatory amino acids in patients with migraine or tension headache," <i>Journal of Neurological Sciences</i> , 156, pgs. 102-106 (1998)					
EXAMINER				DATE CONSIDERED			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							